Education
About Us
Working with TipRanks
Follow Us
scPharmaceuticals Inc (SCPH)
NASDAQ:SCPH
SCPH Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.94 - $6.28
Previous CloseN/A
Volume61.66K
Average Volume (3M)1.58M
Market Cap
$293.67M
Enterprise Value$216.31M
Total Cash (Recent Filing)$40.81M
Total Debt (Recent Filing)$52.45M
Price to Earnings (P/E)―
Beta1.31
Next Earnings
Nov 05, 2025EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding53,298,298
10 Day Avg. Volume3,992,059
30 Day Avg. Volume1,577,184
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.74
Enterprise Value/Revenue4.33
Enterprise Value/Gross Profit6.32
Enterprise Value/Ebitda-2.62
Forecast
1Y Price Target
$11.84Price Target Upside112.19% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Cost EfficiencyThe autoinjector could reduce costs associated with Furoscix by 70-75%, indicating potential for increased efficiency.
Market AdoptionThe rapid adoption of Furoscix in chronic kidney disease among nephrologists suggests a strong market acceptance.
Bears Say
Acquisition InterestNo additional bidders are expected, suggesting limited competitive interest in acquiring scPharmaceuticals beyond the current agreement with MannKind.
Downgrade In RecommendationAnalyst downgrades scPharmaceuticals shares to Hold from Buy, reflecting a cautious stance on future stock price appreciation.
scPharmaceuticals News
SCPH FAQ
What was scPharmaceuticals Inc’s price range in the past 12 months?
scPharmaceuticals Inc lowest stock price was $1.94 and its highest was $6.28 in the past 12 months.
What is scPharmaceuticals Inc’s market cap?
scPharmaceuticals Inc’s market cap is $293.67M.
When is scPharmaceuticals Inc’s upcoming earnings report date?
scPharmaceuticals Inc’s upcoming earnings report date is Nov 05, 2025 which is in 60 days.
How were scPharmaceuticals Inc’s earnings last quarter?
scPharmaceuticals Inc released its earnings results on Aug 07, 2025. The company reported -$0.34 earnings per share for the quarter, missing the consensus estimate of -$0.298 by -$0.042.
Is scPharmaceuticals Inc overvalued?
According to Wall Street analysts scPharmaceuticals Inc’s price is currently Undervalued.
Does scPharmaceuticals Inc pay dividends?
scPharmaceuticals Inc does not currently pay dividends.
What is scPharmaceuticals Inc’s EPS estimate?
scPharmaceuticals Inc’s EPS estimate is -0.23.
How many shares outstanding does scPharmaceuticals Inc have?
scPharmaceuticals Inc has 53,298,298 shares outstanding.
What happened to scPharmaceuticals Inc’s price movement after its last earnings report?
scPharmaceuticals Inc reported an EPS of -$0.34 in its last earnings report, missing expectations of -$0.298. Following the earnings report the stock price went down -7.585%.
Which hedge fund is a major shareholder of scPharmaceuticals Inc?
Currently, no hedge funds are holding shares in SCPH
scPharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$11.84 (112.19% Upside)
$11.84 (112.19% Upside)
Blogger Sentiment
Bullish
SCPH Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.7%
Last 30 Days ▼ 8.5%
Last 30 Days ▼ 8.5%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
9.62%
12-Months-Change
Fundamentals
Return on Equity
-934.02%
Trailing 12-Months
Asset Growth
22.61%
Trailing 12-Months
Company Description
scPharmaceuticals Inc
scPharmaceuticals Inc. is a biotechnology company focused on the development and commercialization of innovative pharmaceutical products that utilize its proprietary subcutaneous drug delivery technology. The company operates primarily in the healthcare sector, with a core focus on providing treatments for patients with chronic conditions, particularly in the areas of heart failure and other serious illnesses. scPharmaceuticals aims to enhance patient outcomes and improve the convenience of administering medications through its products, which include its lead product candidate, Furoscix, a subcutaneous formulation of furosemide for the treatment of worsening heart failure.
SCPH Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected strong revenue and dosage growth, successful launches, and strategic positioning for future growth through regulatory and market dynamics. However, increased costs and cash flow challenges were noted, along with uncertainties in IDN fulfillment rates.View all SCPH earnings summariesSCPH Stock 12 Month Forecast
Average Price Target
$11.84
▲(112.19% Upside)
Technical Analysis
Ownership Overview
17.68% Insiders
6.97% Mutual Funds
49.45% Other Institutional Investors
20.21% Public Companies and
Individual Investors